OFIX · Orthofix Medical Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Orthofix raised full-year 2026 guidance, with net sales now $845M–$855M and adjusted EBITDA $95M–$98M, reflecting the restoration of Medicare reimbursement for bone growth stimulators and an approximate $15M European distributor inventory purchase tied to MDR transition, partially offset by ongoing softness among smaller U.S. spine distributors.
- + Raised full-year 2026 net sales guidance to $845M–$855M, an increase of $7M from prior outlook.
- + Raised full-year 2026 adjusted EBITDA guidance to $95M–$98M, returning to the level expected before the Medicare reimbursement reduction.
- + Biologics stabilized at approximately flat year-over-year, the second consecutive quarter of improved performance after double-digit declines in 2025.
- − Ongoing softness among smaller U.S. spine distributors expected to continue through the balance of the year.
- − Adjusted gross margin declined to 71.7% from 72.7% in Q2 2025 due to unfavorable geographic mix.
- − European MDR distributor arrangement creates an approximately $22 million net sales headwind in 2027 while MDR requirements are completed.
- − European distributor arrangement creates a temporary free cash flow timing headwind in 2026 as cash receipts are projected in 2027 while inventory cash outflows occur this year.
- − GAAP net loss of $(15.8) million in Q2 2026 with net loss per share of $(0.39).
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OFIX
this stock
Orthofix Medical Inc.
|
$353.97M | -41.1% | +2.9% | — | 5.8% |
|
ABT
Abbott Laboratories
|
$178.08B | -18.6% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$117.19B | -5.3% | +8.4% | 22.6 | 0.9% |
|
SYK
Stryker Corp
|
$103.43B | -21.6% | +11.2% | 27.9 | 2.0% |
|
BSX
Boston Scientific Corp
|
$62.29B | -54.9% | +12.5% | 17.4 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OFIX | -4.1% | -12.3% | -23.4% | -4.9% | -41.1% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -2.9% | -10.5% | -41.2% | -4.5% | -53.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.